Abstract
Treating M. abscessus infection is challenging due to the potent β-lactamase BlaMab (Beta-lactamase of M. abscessus). Avibactam is a non-β-lactam, β-lactamase inhibitor shown to inhibit BlaMab. We tested whether avibactem can render piperacillin effective against M. Abscessus. In-vitro, avibactam enhanced the activity of piperacillin by 16-32 fold, with no significant effect on meropenem. In an in-vivo Galleria mellonella model, meropenem and piperacillin/avibactam significantly decreased infection burden compared to untreated controls. Neither piperacillin nor avibactam alone had a significant effect.
Keywords:
Avibactam; Combination treatment; MIC; Mycobacterium abscessus; Piperacillin.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Azabicyclo Compounds / administration & dosage
-
Azabicyclo Compounds / pharmacology
-
Azabicyclo Compounds / therapeutic use*
-
Disease Models, Animal
-
Drug Combinations
-
Drug Synergism
-
Meropenem / therapeutic use
-
Microbial Sensitivity Tests
-
Moths
-
Mycobacterium Infections, Nontuberculous / drug therapy*
-
Mycobacterium abscessus / drug effects*
-
Piperacillin / administration & dosage
-
Piperacillin / pharmacology
-
Piperacillin / therapeutic use*
-
beta-Lactamase Inhibitors / therapeutic use*
-
beta-Lactamases
Substances
-
Azabicyclo Compounds
-
Drug Combinations
-
beta-Lactamase Inhibitors
-
avibactam
-
beta-Lactamases
-
Meropenem
-
Piperacillin